Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply

N Engl J Med. 2022 May 5;386(18):1768. doi: 10.1056/NEJMc2202778.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Arthritis, Rheumatoid* / complications
  • Arthritis, Rheumatoid* / drug therapy
  • Humans
  • Neoplasms*
  • Piperidines / adverse effects
  • Pyrimidines / adverse effects

Substances

  • Piperidines
  • Pyrimidines
  • tofacitinib